For the Following Weekly Period:
November 22nd-28th, 2021 or Thanksgiving Week 2021
NEW YORK, NY -- November 29, 2021 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a New York based diversified Life
Sciences Company, today announced that it has generated record
weekly net E-Commerce revenue (“sales”), for the following period:
Monday November 22, 2021 through Sunday November 28, 2021. The
Company’s net E-Commerce sales, for this one-week period, have
exceeded $22,000 for the first time. The Company is
confident about its business prospects for the remainder of
Calendar Year 2021 and beyond.
Throughout its current operating Quarter
(3rd Fiscal Quarter 2022), the Company has
experienced an acceleration in revenue growth – concerning its
highest margin E-Commerce business segment. Driving this
revenue growth are several important factors: innovative product
offerings, increased orders from repeat customers, and aggressive
new marketing strategies.
The Company is firmly on track to generate record quarterly
revenue (net revenue), for its 3rd Fiscal Quarter
2022. The Company expects that net revenue generated for
this quarter, when completed, will be substantially greater than
any other previous quarter.
Please visit the Company’s recently upgraded E-Commerce website,
at: https://taurigum.com
Lastly, the Company wishes to congratulate Aegea
Biotechnololgies, Inc. (“Aegea”) on the completed clinical
validation for its new COVID-19 Assay (“Test”). Tauriga
Sciences, Inc. currently holds a meaningful equity stake in
Aegea.
** Please Note: 3rd Fiscal Quarter 2022 (Period:
October 1, 2021 – December 31, 2021)
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major
business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main
product line, branded as Tauri-Gum™, consists of a proprietary
supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood
Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon,
Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen
Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini),
(Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), &
(Vitamin D3 Infused Tauri-Gum™ Flavor: Golden
Raspberry). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce
website: www.taurigum.com). Please visit our corporate
website, for additional information, as well as inquiries,
at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 22, 2021, the Company announced that it had
Converted its U.S. Provisional Patent Application (filed on March
17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates two full time
E-Commerce fulfillment centers: one located in Montgomery, Texas
and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Sep 2023 to Sep 2024